|
Balance Sheet Cash Flow Statement 41 Pinelawn Rd. Melville, NY 11747 NY Tel. 631-962-2000 Fax 631-752-3880 |
Type: Public
On the web:
http://www.osip.com
Employees:
514
Employee growth: 5.3%
Fighting disease in small ways is what OSI Pharmaceuticals is all about. The company focuses on small molecule cures for diseases like cancer, allowing for treatment by pill rather than IV infusion. Its top seller Tarceva treats non-small cell lung cancer and pancreatic cancer and is in development for other indications as well. Partner Genentech co-promotes the drug in the US, and it is marketed internationally by Roche. OSI also has a pipeline of drug candidates focused on new anti-cancer compounds. UK subsidiary Prosidion manages the company's small molecule patents for diabetes and obesity treatments, bringing in about $100 million annually. Prosidion also serves as OSI's diabetes and obesity R&D center.
Key numbers for fiscal year ending December, 2008:
Sales: $379.4M
One year growth: 11.2%
Net income: $138.2M
Income growth: 108.4%
Officers:
Chairman: Robert A. (Bob) Ingram
CEO and Director: Colin Goddard
EVP, CFO, and Treasurer: Pierre Legault
Competitors:
Bristol-Myers Squibb
Genentech
Sanofi-Aventis
